Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3

Journal of Biological Chemistry

Volumn 287, Issue 25, 2012, Pages 20904-20912

  Gao, Yiwei ^a   Cimica, Velasco ^a   Reich, Nancy C ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CARCINOMAS; BREAST TUMOR; BREAST TUMOR KINASE; CANCER PROGRESSION; CYTOKINE SIGNALING; CYTOKINE STIMULATION; INHIBITORY EFFECT; JANUS TYROSINE KINASE; NEGATIVE REGULATORS; ONCOGENESIS; PROTEIN BINDS; SH2 DOMAIN; SIGNAL TRANSDUCERS; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR PROGRESSIONS; TYROSINE KINASE; TYROSINE PHOSPHORYLATION;

AMINO ACIDS; CHEMICAL ACTIVATION; DEGRADATION; ENZYMES; PHOSPHORYLATION;

TUMORS;

BREAST TUMOR KINASE; MESSENGER RNA; PROTEIN SH2; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

ARTICLE; BREAST TUMOR KINASE GENE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; GENE; GENE DELETION; GENE EXPRESSION REGULATION; MOLECULAR DYNAMICS; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING 3 GENE;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME ACTIVATION; HELA CELLS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; PROTEOLYSIS; SRC HOMOLOGY DOMAINS; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84862274014     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.334144     Document Type: Article

References (53)

1. Harvey, A. J., Pennington, C. J., Porter, S., Burmi, R. S., Edwards, D. R., Court, W., Eccles, S. A., and Crompton, M. R. (2009) Brk protects breast cancer cells from autophagic cell death induced by loss of anchorage. Am. J. Pathol. 175, 1226-1234
2. Brauer, P. M., and Tyner, A. L. (2010) Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK. Biochim. Biophys. Acta 1806, 66-73
3. Ostrander, J. H., Daniel, A. R., Lofgren, K., Kleer, C. G., and Lange, C. A. (2007) Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res. 67, 4199-4209 (Pubitemid 46815066)
4. Mitchell, P. J., Barker, K. T., Martindale, J. E., Kamalati, T., Lowe, P. N., Page, M. J., Gusterson, B. A., and Crompton, M. R. (1994) Cloning and characterization of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene 9, 2383-2390 (Pubitemid 24228691)
5. Gschwind, A., Fischer, O. M., and Ullrich, A. (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 4, 361-370 (Pubitemid 38579482)
6. Hynes, N. E., and Lane, H. A. (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354 (Pubitemid 40637826)
7. Born, M., Quintanilla-Fend, L., Braselmann, H., Reich, U., Richter, M., Hutzler, P., and Aubele, M. (2005) Simultaneous overexpression of the Her2/neu and PTK6 tyrosine kinases in archival invasive ductal breast carcinomas. J. Pathol. 205, 592-596 (Pubitemid 40514832)
8. Xiang, B., Chatti, K., Qiu, H., Lakshmi, B., Krasnitz, A., Hicks, J., Yu, M., Miller, W. T., and Muthuswamy, S. K. (2008) Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 105, 12463-12468
9. Kamalati, T., Jolin, H. E., Mitchell, P. J., Barker, K. T., Jackson, L. E., Dean, C. J., Page, M. J., Gusterson, B. A., and Crompton, M. R. (1996) Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J. Biol. Chem. 271, 30956-30963 (Pubitemid 26404123)
10. Kang, S. A., Lee, E. S., Yoon, H. Y., Randazzo, P. A., and Lee, S. T. (2010) PTK6 inhibits down-regulation of EGF receptor through phosphorylation of ARAP1. J. Biol. Chem. 285, 26013-26021
11. Shen, C. H., Chen, H. Y., Lin, M. S., Li, F. Y., Chang, C. C., Kuo, M. L., Settleman, J., and Chen, R. H. (2008) Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion. Cancer Res. 68, 7779-7787
12. Chen, H. Y., Shen, C. H., Tsai, Y. T., Lin, F. C., Huang, Y. P., and Chen, R. H. (2004) Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol. Cell Biol. 24, 10558-10572
13. Qiu, H., and Miller, W. T. (2004) Role of the Brk SH3 domain in substrate recognition. Oncogene 23, 2216-2223 (Pubitemid 38482536)
14. Qiu, H., and Miller, W. T. (2002) Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition. J. Biol. Chem. 277, 34634-34641
15. Liu, L., Gao, Y., Qiu, H., Miller, W. T., Poli, V., and Reich, N. C. (2006) Identification of STAT3 as a specific substrate of breast tumor kinase. Oncogene 25, 4904-4912 (Pubitemid 44201181)
16. Weaver, A. M., and Silva, C. M. (2007) Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6. Breast Cancer Res. 9, R79
17. Schindler, C., Levy, D. E., and Decker, T. (2007) JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 282, 20059-20063 (Pubitemid 47099977)
18. Yu, H., Pardoll, D., and Jove, R. (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798-809
19. Ludyga, N., Anastasov, N., Gonzalez-Vasconcellos, I., Ram, M., Höfler, H., and Aubele, M. (2011) Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signaling in breast cancer. Mol. Biosyst. 7, 1603-1612
20. Levy, D. E., and Darnell, J. E., Jr. (2002) Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3, 651-662 (Pubitemid 34987786)
21. Wegenka, U. M., Buschmann, J., Lütticken, C., Heinrich, P. C., and Horn, F. (1993) Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the post-translational level. Mol. Cell Biol. 13, 276-288 (Pubitemid 23006905)
22. Lütticken, C., Wegenka, U. M., Yuan, J., Buschmann, J., Schindler, C., Ziemiecki, A., Harpur, A. G., Wilks, A. F., Yasukawa, K., Taga, T., and et al. (1994) Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 263, 89-92 (Pubitemid 24076262)
23. Akira, S., Nishio, Y., Inoue, M., Wang, X. J., Wei, S., Matsusaka, T., Yoshida, K., Sudo, T., Naruto, M., and Kishimoto, T. (1994) Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77, 63-71
24. Taga, T., and Kishimoto, T. (1997) Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15, 797-819 (Pubitemid 27169299)
25. Starr, R., Willson, T. A., Viney, E. M., Murray, L. J., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., and Hilton, D. J. (1997) A family of cytokine-inducible inhibitors of signaling. Nature 387, 917-921
26. Croker, B. A., Krebs, D. L., Zhang, J. G., Wormald, S., Willson, T. A., Stanley, E. G., Robb, L., Greenhalgh, C. J., Forster, I., Clausen, B. E., Nicola, N. A., Metcalf, D., Hilton, D. J., Roberts, A. W., and Alexander, W. S. (2003) SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4, 540-545 (Pubitemid 36701336)
27. Babon, J. J., Kershaw, N. J., Murphy, J. M., Varghese, L. N., Laktyushin, A., Young, S. N., Lucet, I. S., Norton, R. S., and Nicola, N. A. (2012) Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 36, 239-250
28. Boyle, K., Zhang, J. G., Nicholson, S. E., Trounson, E., Babon, J. J., McManus, E. J., Nicola, N. A., and Robb, L. (2009) Deletion of the SOCS box of suppressor of cytokine signaling 3 (SOCS3) in embryonic stem cells reveals SOCS box-dependent regulation of JAK but not STAT phosphorylation. Cell Signal. 21, 394-404
29. Grivennikov, S. I., and Karin, M. (2010) Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21, 11-19
30. Iliopoulos, D., Hirsch, H. A., and Struhl, K. (2009) An epigenetic switch involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139, 693-706
31. He, B., You, L., Uematsu, K., Zang, K., Xu, Z., Lee, A. Y., Costello, J. F., McCormick, F., and Jablons, D. M. (2003) SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc. Natl. Acad. Sci. U.S.A. 100, 14133-14138 (Pubitemid 37499203)
32. Liu, L., McBride, K. M., and Reich, N. C. (2005) STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3. Proc. Natl. Acad. Sci. U.S.A. 102, 8150-8155 (Pubitemid 40800058)
33. Treier, M., Staszewski, L. M., and Bohmann, D. (1994) Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78, 787-798 (Pubitemid 24294454)
34. Campanero, M. R., and Flemington, E. K. (1997) Regulation of E2F through ubiquitin-proteasome-dependent degradation: stabilization by the pRB tumor suppressor protein. Proc. Natl. Acad. Sci. U.S.A. 94, 2221-2226 (Pubitemid 27136855)
35. Senn, J. J., Klover, P. J., Nowak, I. A., Zimmers, T. A., Koniaris, L. G., Furlanetto, R. W., and Mooney, R. A. (2003) Suppressor of cytokine signaling- 3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J. Biol. Chem. 278, 13740-13746 (Pubitemid 36799910)
36. He, B., You, L., Uematsu, K., Matsangou, M., Xu, Z., He, M., McCormick, F., and Jablons, D. M. (2003) Cloning and characterization of a functional promoter of the human SOCS-3 gene. Biochem. Biophys. Res. Commun. 301, 386-391 (Pubitemid 36279250)
37. Croker, B. A., Kiu, H., and Nicholson, S. E. (2008) SOCS regulation of the JAK/STAT signaling pathway. Semin Cell Dev. Biol. 19, 414-422
38. Piessevaux, J., Lavens, D., Peelman, F., and Tavernier, J. (2008) The many faces of the SOCS box. Cytokine Growth Factor Rev. 19, 371-381
39. Babon, J. J., McManus, E. J., Yao, S., DeSouza, D. P., Mielke, L. A., Sprigg, N. S., Willson, T. A., Hilton, D. J., Nicola, N. A., Baca, M., Nicholson, S. E., and Norton, R. S. (2006) The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability. Mol. Cell 22, 205-216 (Pubitemid 44316440)
40. Sasaki, A., Yasukawa, H., Suzuki, A., Kamizono, S., Syoda, T., Kinjyo, I., Sasaki, M., Johnston, J. A., and Yoshimura, A. (1999) Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4, 339-351 (Pubitemid 29359449)
41. Nicholson, S. E., De Souza, D., Fabri, L. J., Corbin, J., Willson, T. A., Zhang, J. G., Silva, A., Asimakis, M., Farley, A., Nash, A. D., Metcalf, D., Hilton, D. J., Nicola, N. A., and Baca, M. (2000) Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc. Natl. Acad. Sci. U.S.A. 97, 6493-6498 (Pubitemid 30412741)
42. Bergamin, E., Wu, J., and Hubbard, S. R. (2006) Structural basis for phosphotyrosine recognition by suppressor of cytokine signaling-3. Structure 14, 1285-1292 (Pubitemid 44176372)
43. De Souza, D., Fabri, L. J., Nash, A., Hilton, D. J., Nicola, N. A., and Baca, M. (2002) SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities. Biochemistry 41, 9229-9236 (Pubitemid 34787281)
44. Orr, S. J., Morgan, N. M., Buick, R. J., Boyd, C. R., Elliott, J., Burrows, J. F., Jefferies, C. A., Crocker, P. R., and Johnston, J. A. (2007) SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses. J. Biol. Chem. 282, 3418-3422 (Pubitemid 47084418)
45. Rui, L., Yuan, M., Frantz, D., Shoelson, S., and White, M. F. (2002) SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 277, 42394-42398 (Pubitemid 35257562)
46. Liu, E., Côté, J. F., and Vuori, K. (2003) Negative regulation of FAK signaling by SOCS proteins. EMBO J. 22, 5036-5046 (Pubitemid 37222024)
47. Elliott, J., Hookham, M. B., and Johnston, J. A. (2008) The suppressors of cytokine signaling E3 ligases behave as tumour suppressors. Biochem. Soc. Trans. 36, 464-468 (Pubitemid 351839356)
48. Haegebarth, A., Bie, W., Yang, R., Crawford, S. E., Vasioukhin, V., Fuchs, E., and Tyner, A. L. (2006) Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine. Mol. Cell Biol. 26, 4949-4957 (Pubitemid 43955811)
49. Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon- Thomas, S., Niu, G., Kay, H., Mule, J., Kerr, W. G., Jove, R., Pardoll, D., and Yu, H. (2005) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11, 1314-1321 (Pubitemid 41752912)
50. Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., and Darnell, J. E., Jr. (1999) Stat3 as an oncogene. Cell 98, 295-303 (Pubitemid 29380565)
51. Chiarle, R., Simmons, W. J., Cai, H., Dhall, G., Zamo, A., Raz, R., Karras, J. G., Levy, D. E., and Inghirami, G. (2005) Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 11, 623-629 (Pubitemid 40868302)
52. Ying, M., Li, D., Yang, L., Wang, M., Wang, N., Chen, Y., He, M., and Wang, Y. (2010) Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma. J. Cancer Res. Clin. Oncol. 136, 1617-1626
53. Ikeda, F., and Dikic, I. (2008) Atypical ubiquitin chains: new molecular signals. 'Protein Modifications: Beyond the Usual Suspects' review series. EMBO Rep. 9, 536-542 (Pubitemid 351772916)